Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorder diagnosis and treatment, announced today that it has signed a supply agreement with Raffles Medical for its neurodegenerative brain imaging analysis software, Neurophet AQUA.
Neurophet AQUA is a neurodegenerative brain imaging analysis software that performs ultra-fast quantitative analysis of patients' brain MRI scans, enabling the assessment of brain atrophy and white matter degeneration. It quantifies structural changes in the brain—such as atrophy and white matter alterations—observed in neurodegenerative diseases including Alzheimer's disease and vascular dementia, and delivers customised analysis reports tailored to individual patients.
Raffles Medical is the primary healthcare arm of Raffles Medical Group, operating a network of more than 100 multi-disciplinary clinics across Singapore and Asia. The clinic network is integrated with Raffles Hospital and Raffles Specialist Centres, providing patients with access to specialist and diagnostic services.
Jake Junkil Been, Co-CEO of Neurophet, said, "We are very pleased to supply Neurophet's products to Raffles Medical, following collaborations with public institutions such as the Dementia Research Centre at Nanyang Technological University, National University of Singapore, and Singapore General Hospital."
